Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Health Plan LHRH Prior Auth Coverage | O…
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy N/A

    Pituitary suppressive agents (LHRH) prior authorization

    Customize your policy alerts

    Sign up for all Geisinger Health Plan policy alerts

    Know when Geisinger Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization form and requirements for pituitary suppressive LHRH agents (for indications including central precocious puberty, gender dysphoria, endometriosis, preservation of ovarian function, and specified oral GnRH antagonist combination products); intended for prescribers seeking coverage.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyPituitary suppressive agents (LHRH) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 3, 2022
    Next Review DateN/A
    Key ActionSubmit completed prior authorization form with required clinical documentation via the PromptPA portal or fax.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1/3/2022form effective date
    multipleindications covered
    570-271-5610fax
    PromptPAelectronic

    Coverage Criteria and Indication-Specific Requirements

    Central Precocious Puberty criteria

    Covered when ALL applicable indication-specific criteria on the form are met and documentation is submitted:

    Central Precocious Puberty: Medication is prescribed by or in consultation with a pediatric endocrinologist AND ((patient is female AND age ≤11 AND onset of secondary sexual characteristics earlier than 8 years of age) OR (patient is male AND age ≤12 AND onset of secondary sexual characteristics earlier than 9 years of age))

    Document specialist consult, patient sex, age, and onset timing; submit DX code and supporting documentation.

    Gender dysphoria criteria

    Covered when ALL the following are met for gender dysphoria:

    Gender Dysphoria: Medication is prescribed by or in consultation with an adult or pediatric endocrinologist or other provider with experience/training in transgender medicine AND medication is prescribed in a manner consistent with current WPATH standards of care or other medical literature

    Document provider experience/training and adherence to WPATH or equivalent standards.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyPituitary suppressive agents (LHRH) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 3, 2022
    Next Review DateN/A
    Key ActionSubmit completed prior authorization form with required clinical documentation via the PromptPA portal or fax.
    SourceLink
    On This Page
    Coverage Criteria and Indication-Specific RequirementsDiagnosis Codes and Age ThresholdsAuthorization, Documentation, and Step Therapy RequirementsStep Therapy RequirementsKey Definitions and Diagnostic RequirementsQuantity and Dose LimitsSite of Care RestrictionsBackground and Clinical Context

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Endometriosis criteria

    Covered when ALL the following are met for endometriosis:

    Endometriosis: Medication is prescribed by or in consultation with a gynecologist AND diagnosis confirmed by laparoscopy AND diagnosis supported by chart documentation of adequate work-up including the clinical rationale for the diagnosis AND tried and failed NSAIDs or has a contraindication or intolerance to NSAIDs AND failed a 3-month trial of oral contraceptives or has a contraindication or intolerance to oral contraceptives

    Submit laparoscopy report and documentation of NSAID and oral contraceptive trials or stated contraindications/intolerances.

    Preservation of ovarian function criteria

    Covered when ALL the following are met for preservation of ovarian function:

    Preservation of ovarian function: Patient is receiving cancer treatment that is associated with premature ovarian failure based on NCCN guidelines or peer-reviewed medical literature

    Document the cancer treatment and provide supporting citation(s) to NCCN guidelines or peer-reviewed literature as applicable.

    Behavioral health assessment requirement

    Covered when ALL the following are met for specified combination oral products (MYFEMBREE, ORIAHNN, ORILISSA):

    Behavioral health and monitoring: For MYFEMBREE, ORIAHNN, and ORILISSA: patient has a history of depression and/or suicidal thoughts or behaviors OR is receiving treatment for depression and/or suicidal thoughts or behaviors AND had a behavioral health assessment prior to use of the requested medication

    Behavioral health assessment documentation is required; submit records showing history or ongoing treatment and the pre-treatment assessment.

    Heavy menstrual bleeding (fibroids) criteria

    Covered when ALL the following are met for heavy menstrual bleeding due to fibroids with specific combination products:

    Heavy menstrual bleeding with fibroids: For MYFEMBREE and ORIAHNN: patient is being treated for heavy menstrual bleeding associated with uterine leiomyomas (fibroids) AND patient is pre-menopausal AND tried and failed a 3-month trial of contraceptives or has a contraindication or intolerance to contraceptives

    Document fibroid-related heavy menstrual bleeding, menopausal status, and contraceptive trial or documented contraindication/intolerance.

    The form does not list any blanket exclusions for pituitary suppressive LHRH agents. Coverage is determined by meeting the indication‑specific criteria documented on the prior authorization form (for example, criteria for central precocious puberty, gender dysphoria, endometriosis, preservation of ovarian function, or specified oral combination products) and by any applicable preferred vs non‑preferred drug rules referenced on the form. Providers should refer to the Geisinger preferred drug list at the URL on the form when considering preferred/non‑preferred status.

    Requests that do not meet the indication‑specific checklist items on the form may be considered not medically necessary. In addition, lack of required supporting documentation — for example, absence of the required specialist consultation when specified (such as pediatric endocrinologist for CPP or gynecologist for endometriosis), missing diagnostic confirmation (e.g., laparoscopy report for endometriosis), or missing documentation of trial/failure or contraindication for preferred agents — may result in denial of the request.

    Diagnosis Codes and Age Thresholds

    Required diagnosis codeICD-10
    DX code ( required )Diagnosis code to be submitted on form
    Age thresholds for Central Precocious Puberty (CPP)
    Female age threshold≤11 years with onset of secondary sexual characteristics earlier than 8 years
    Male age threshold≤12 years with onset of secondary sexual characteristics earlier than 9 years
    Prescriber requirementMedication prescribed by or in consultation with a pediatric endocrinologist

    Authorization, Documentation, and Step Therapy Requirements

    Prior Authorization

    Prior authorization required — submit completed form and supporting documentation

    Prior authorization is required for pituitary suppressive LHRH agents. Providers must submit the completed prior authorization form and all supporting documentation via the PromptPA portal or fax to Geisinger Health Plan.

    • Submit completed Pituitary Suppressive Agents, LHRH prior authorization form (form effective 1/3/2022).
    • Electronic submission: PromptPA https://ghp.promptpa.com; Fax: 570-271-5610.
    Step Therapy

    Step therapy / prior trials required for non-preferred agents and endometriosis

    For non-preferred LHRH agents, the request requires documentation of trial and failure of, or a contraindication or intolerance to, preferred drugs in this class. For endometriosis, approval also requires prior trial and failure of NSAIDs and a failed 3-month trial of oral contraceptives (unless contraindicated/intolerant).

    • If non-preferred agent: document trial and failure of preferred class agents or documented contraindication/intolerance and include supporting records.
    • Endometriosis-specific: document tried and failed NSAIDs (or contraindication/intolerance) and failed a 3-month trial of oral contraceptives (or contraindication/intolerance).
    Documentation Required

    Required documentation to accompany the PA form

    Include the completed prior authorization form with beneficiary and prescriber details, the diagnosis and DX (ICD) code, and supporting clinical documentation addressing the indication-specific checklist items.

    • Completed form fields: prescriber name, specialty, NPI, beneficiary name, beneficiary ID, DOB, contact information, prescriber signature and date.
    • Diagnosis: submit the diagnosis and DX code (required) on the form.
    • Supporting clinical documentation: specialist consultation notes when required (e.g., pediatric endocrinologist for CPP, gynecologist for endometriosis), laparoscopy report for endometriosis, documentation of trials of therapies (NSAIDs, OCs) or reasons for contraindication/intolerance, behavioral health assessment for specified products.
    Denial Risk

    Non-preferred agent requests require documented trial/failure or contraindication/intolerance

    Requests for non-preferred LHRH agents must include documentation of trial and failure of, or contraindication or intolerance to, preferred drugs in this class; lack of such documentation may lead to denial.

    • Refer to the preferred drug list at https://papdl.com/preferred-drug-list for identification of preferred vs non-preferred agents.
    • If 'Yes' to prior trial/failure, submit documentation as indicated on the form; if 'No', the request may be denied.

    Step Therapy Requirements

    RequirementDetails / Provider action
    Step therapy requirement for non-preferred agentsFor a non-preferred pituitary suppressive agent (LHRH), the beneficiary must have a history of trial and failure of, or a documented contraindication or intolerance to, the preferred drugs in this class. Providers must refer to the preferred drug list (https://papdl.com/preferred-drug-list) and submit supporting documentation of the trial/failure or contraindication/intolerance.
    Documentation to submitCheck 'Yes' and submit documentation on the prior authorization form demonstrating the trial and failure or contraindication/intolerance to preferred agents; if 'No' is selected, the requirement is not met. The form directs providers to submit documentation with the request.
    Where to verify preferred agentsRefer to the Geisinger preferred drug list at https://papdl.com/preferred-drug-list for the current list of preferred and non-preferred drugs in this class when determining required prior trials.

    Key Definitions and Diagnostic Requirements

    Central Precocious Puberty (CPP) — definition
    DefinitionEarly onset of secondary sexual characteristics meeting age thresholds for CPP
    Female thresholdsFemale ≤11 years of age with onset earlier than 8 years
    Male thresholdsMale ≤12 years of age with onset earlier than 9 years
    Specialist involvementMedication prescribed by or in consultation with a pediatric endocrinologist
    Endometriosis — definition and required work-up
    Diagnostic confirmationDiagnosis confirmed by laparoscopy
    Supporting documentationDiagnosis must be supported by chart documentation of adequate work-up including clinical rationale
    Required prior trials/work-upTried and failed NSAIDs (or contraindication/intolerance) and failed a 3-month trial of oral contraceptives (or contraindication/intolerance)
    Prescriber requirementMedication prescribed by or in consultation with a gynecologist

    Quantity and Dose Limits

    Pituitary suppressive agents (class) — quantity/daily dose limits
    Quantity/Daily Dose LimitsQuantity/Daily Dose Limits for pituitary suppressive agents are listed on Geisinger Health Plan's website at https://www.geisinger.org/health-plan/find/covered-drug-pharmacy
    Preferred drug list referenceRefer to https://papdl.com/preferred-drug-list for preferred and non-preferred drugs in this class
    Prior authorization formPrior authorization and quantity limits information available on Geisinger Health Plan website (see above)

    Site of Care Restrictions

    Note

    No site-of-care restrictions specified

    No site-of-care restrictions are specified on the prior authorization form for these agents.

    • Setting noted on form: office (no restrictions specified).

    Background and Clinical Context

    Luteinizing‑hormone‑releasing hormone (LHRH, also called GnRH) pituitary suppressive agents are medications used to suppress gonadotropin release from the pituitary. The form indicates their typical clinical uses include treatment of central precocious puberty (CPP) — where therapy must be prescribed by or in consultation with a pediatric endocrinologist and meet age/onset thresholds — suppression of puberty for patients with gender dysphoria (when prescribed by or in consultation with providers experienced in transgender medicine and in a manner consistent with current standards of care), management of endometriosis (when prescribed by or in consultation with a gynecologist and with diagnostic confirmation such as laparoscopy), and preservation of ovarian function during gonadotoxic cancer treatment. The form documents the specific clinical checklist items and supporting documentation required for these indications.